Santen Pharmaceutical Co., Ltd.
4536.T
Tokyo Stock Exchange2,218.50
JPY
-17.50
- -
Santen Pharmaceutical Co., Ltd.
4536.T
(Tokyo Stock Exchange)
Recent
price
2,218.50
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Santen Pharmaceutical Co., Ltd. (4536.T) specializes in the research, development, manufacturing, marketing, and sales of prescription pharmaceuticals, over-the-counter products, and medical devices focused on ophthalmology; its core offerings address glaucoma (including brands like SETANEO Ophthalmic Solution 0.002% launched in Japan in October 2025, DIQUAS LX Ophthalmic Solution 3% for dry eye with resumed shipments announced in November 2025), dry eye disease, ocular allergies, uveitis, myopia, meibomian gland dysfunction, pterygium, and retinal diseases such as diabetic macular edema; the company also advances pipelines in ROCK inhibitors via prior licensing with Aerie Pharmaceuticals, VEGF inhibitors like Beovu and Lucentis through an exclusive promotion and distribution agreement with Santen Korea in October 2025, and other innovative therapies targeting angiogenesis and fibrosis. Founded in 1890 and headquartered in Osaka, Japan, Santen operates globally with manufacturing plants in Japan (Hōdatsushimizu, Ishikawa), Finland (Tampere), and China (Suzhou), an R&D center in Ikoma, Nara, Japan, and subsidiaries across more than 60 countries and regions including the United States, Europe (Netherlands, Finland, UK, Spain, Switzerland, Italy, France, Germany, Sweden), Asia (China, South Korea, Taiwan, India, Thailand, Malaysia, Philippines, Singapore, Vietnam, Hong Kong), and others, serving patients, healthcare professionals, and consumers in these markets as the market leader for prescription ophthalmic pharmaceuticals in Japan. Recent strategic developments include an exclusive licensing agreement with RemeGen in August 2025 for RC28-E intravitreal injection (with biologic license application accepted in China for diabetic macular edema in September 2025), a licensing deal with Cloudbreak Pharma in September 2024 for a topical pterygium treatment, a collaboration with SERI announced in December 2025 to advance disease-modifying therapies for major eye diseases, the launch of SETANEO in Japan in October 2025, and an exclusive promotion agreement for Beovu and Lucentis in South Korea in October 2025, alongside ongoing share buybacks completed in November 2025 and treasury share disposals for performance-linked remuneration.